


COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~striketrough~~ or [[double brackets]]
and additions by underlining)

1-8 (canceled)

9 (currently amended): A compound ~~according to claim 1~~ of the formula (I),



(I)

the racemic-diastereomeric mixtures and optical isomers of said compound of formula (I) and pharmaceutically-acceptable salts thereof,

wherein

----- represents an optional bond;

R¹ is H;

R² is H;

R³ is -CH₂-indol-3-yl, -(CH₂)₄-NH-CO-O-t-Bu or -(CH₂)₄-NH₂;

R⁴ is H or -(CH₂)_m-A¹;

A¹ is -C(=Y)-N(X¹X²), -C(=Y)-X², -C(=NH)-X² or X²;

Y is O or S;

X¹ is H, (C₁-C₁₂)alkyl, -(CH₂)_m-NH-(C₁-C₆)alkyl, -(CH₂)_m-N-di-(C₁-C₆)alkyl or -(CH₂)_m-aryl;

X² is -(CH₂)_m-Y¹-X³ or optionally substituted (C₁-C₁₂)alkyl;

Y¹ is O, S, NH, C=O, (C₂-C₁₂)alkenyl having one or more double bonds,

-NH-CO-, -CO-NH-, -NH-CO-O-(CH₂)_m-, -C≡C-, SO₂ or a bond;


X³ is H, an optionally substituted moiety selected from the group consisting of (C₁-

C₁₂)alkyl, (C₃-C₈)cycloalkyl, (C₁-C₁₂)alkoxy, aryloxy, (C₁-C₁₂)alkylamino, N,N-di-(C₁-C₁₂)alkylamino, -CH-di-(C₁-C₁₂)alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl,

X⁴ for each occurrence is independently -(CH₂)_m-Y³-X⁵;

Y³ is -C(O)-, -C(O)O- or a bond;

X⁵ is hydroxy, (C₁-C₁₂)alkyl, amino, (C₁-C₁₂)alkylamino, N,N-di-(C₁-C₁₂)alkylamino, or an optionally substituted moiety selected from the group consisting of aryl, aryl(C₁-C₄)alkyl, furanyl, pyridinyl, indolyl, -CH(phenyl)₂,



where m for each occurrence is independently 0 or an integer from 1 to 6;

R⁵ is phenyl, o-methoxyphenyl, p-Br-phenyl, p-nitro-phenyl or p-N,N-diethylamino-phenyl;

R⁶ is H.

10 (canceled)

11 (original): A compound according to claim 9 wherein R⁵ is phenyl and R³ is -(CH₂)-indol-3-yl and the stereochemistry at the carbon to which R³ is attached is the R-configuration.

12-29 (canceled)

30 (withdrawn – currently amended): A pharmaceutical composition comprising a compound according to claim [[1]] 9 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

31-33 (canceled)

34 (withdrawn – currently amended): A method of treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, ~~gonadotropinoma~~, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, ~~hypotension~~, postprandial

hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas, in a subject in need thereof, which comprises administering a compound according to claim [[1]] 9 or a pharmaceutically acceptable salt thereof to said subject.

35 (withdrawn – currently amended): A method of treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, ~~Nephropathy~~, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, acute or chronic pancreatitis, gastrointestinal hormone secreting tumors, ~~angiogenesis, inflammatory disorders~~, chronic allograft rejection, ~~angioplasty~~, graft vessel bleeding or gastrointestinal bleeding in a subject in need thereof, which comprises administering a compound according to claim [[1]] 9 or a pharmaceutically acceptable salt thereof to said subject.

36-43 (canceled)